This trial is testing whether adding daratumumab to lenalidomide can help people with newly diagnosed multiple myeloma who are positive for MRD (as determined by next generation sequencing).
1 Primary · 10 Secondary · Reporting Duration: Up to 4.1 years
Active Control
Experimental Treatment
214 Total Participants · 2 Treatment Groups
Primary Treatment: Daratumumab · No Placebo Group · Phase 3
Age 18 - 79 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: